Tag: Biotechnology

Impact Newswire brings you the latest in Biotechnology news.

Vianautis
Untied Kingdom

ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer

ViaNautis Bio (“ViaNautis” or the “Company”), a groundbreaking nanomedicine company at the forefront of genetic therapies, today announces the appointment of Dr Adi Hoess as Chief Executive Officer of ViaNautis. He will succeed Co-Founder and CEO Dr Francesca Crawford who has been stepping down from her role. Dr Adi Hoess brings a wealth of experience to ViaNautis, having previously served as CEO of Nasdaq-listed German … Continue reading ViaNautis Bio appoints Dr Adi Hoess as Chief Executive Officer

Impact Newswire
axolbio
Europe

Axol Bioscience acquires Phenocell to advance human disease models

Acquisition expands Axol’s iPSC-derived cell models and service offering to include ophthalmology and dermatology CAMBRIDGE / EDINBURGH, UK, and GRASSE, FRANCE, October 2024: Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem cell (iPSC) technology provider for drug discovery, today announced it has fully acquired Phenocell SAS, a pioneer in iPSC-based products and bioassays for skin and retinal disorders. The acquisition extends Axol’s portfolio of iPSC-derived cell … Continue reading Axol Bioscience acquires Phenocell to advance human disease models

Impact Newswire
Seaport Therapeutics
United States

Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Financing led by General Atlantic with participation from T. Rowe Price Associates, Foresite Capital, Invus, Goldman Sachs Alternatives, Canada Pension Plan Investment Board (CPP Investments) as well as other new investors Founding investors ARCH Venture Partners, Sofinnova Investments, Third Rock Ventures, and PureTech Health also participated Proceeds will support key clinical milestones in Seaport’s pipeline of first and best-in-class neuropsychiatric medicines BOSTON, October 21, 2024 … Continue reading Seaport Therapeutics Closes $225 Million Oversubscribed Series B Financing Round

Impact Newswire
Acticor Biotech
Europe

Acticor Biotech appoints François Guilletas Chief Financial Officer

Paris, France, Octobre 14, 2024 – 08:00am CEST – ACTICOR BIOTECH (FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, today announces the appointment of François Guillet as Chief Financial Officer, replacing Éric Cohen who is leaving to pursue other projects. Gilles AVENARD, Chief Executive Officer and founder of Acticor Biotech, comments: “We are delighted to … Continue reading Acticor Biotech appoints François Guilletas Chief Financial Officer

Impact Newswire
Judo Bio
United States

Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO

STRIKE platform to deliver siRNA and other genetic medicines to the kidney for the treatment of systemic diseases and renal diseases Lead pipeline programs use megalin receptors for intracellular delivery of ligand-siRNA conjugates to specific kidney cells to target and silence genes, including solute carrier proteins CAMBRIDGE, Mass., October 7, 2024 — Judo Bio, a biotechnology company pioneering oligonucleotide medicines delivered to the kidney, today announced … Continue reading Judo Bio Launches with $100 Million Financing to Develop Oligonucleotide Therapies Delivered to the Kidney and Appoints Rajiv Patni as CEO

Impact Newswire